Adempas (riociguat) / Bayer, Merck (MSD) - LARVOL DELTA

Investigational randomized controlled trial of patients with inoperable chronic thromboembolic pulmonary hypertension treated with riociguat vs selexipag (ESC-WCC 2025) - No abstract available

Clinical • Cardiovascular • Pulmonary Embolism

Switching sildenafil to riociguat in chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty - the S2R study (ESC-WCC 2025) - No abstract available

Cardiovascular • Pulmonary Embolism

Safety and efficacy of macitentan and riociguat upfront combination therapy in patients with idiopathic pulmonary arterial hypertension at intermediate risk. (ESC-WCC 2025) - No abstract available

Clinical • Combination therapy • Cardiovascular

Treatment and monitoring of CTD-ILDs (ERS 2025) - "We describe recent advances in the treatment of CTD-ILD, including novel data and trials as well as post hoc analyses of clinical trials on mycophenolate, cyclophosmphamide, tocilizumab, rituximab, riociguat and nintedanib. Lastly, we elucidate on peripheral blood cell gene expression profiling as a novel way to identify patients with a better treatment response to mycophenolate."

Rheumatology

RIVERII: Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH (clinicaltrials.gov) - P4 | N=30 | Active, not recruiting | Sponsor: Heidelberg University | Recruiting ➔ Active, not recruiting | Trial completion date: Mar 2026 ➔ Aug 2025 | Trial primary completion date: Mar 2026 ➔ Jul 2025

Enrollment closed • Trial completion date • Trial primary completion date • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases

ESRA: Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH (clinicaltrials.gov) - P2 | N=70 | Active, not recruiting | Sponsor: Heidelberg University | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2026 ➔ Jul 2025 | Trial primary completion date: Oct 2025 ➔ Jul 2025

Enrollment closed • Trial completion date • Trial primary completion date • Cardiovascular • Hypertension • Immunology • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Scleroderma • Systemic Sclerosis

New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025. (PubMed, RMD Open) - "While recent EULAR recommendations have updated the standard of care for SSc, the field is rapidly evolving with novel therapeutic strategies and precision medicine approaches.Traditional immunosuppressive therapies-including mycophenolate mofetil, cyclophosphamide and rituximab-remain essential for controlling skin and lung involvement while autologous haematopoietic stem cell transplantation offers a proven disease-modifying option for selected high-risk patients. Tocilizumab and nintedanib have established roles in lung preservation in SSc-associated interstitial lung disease (SSc-ILD). In pulmonary arterial hypertension (PAH), early combination therapy with endothelin receptor antagonists and phosphodiesterase-5 inhibitors, complemented by newer agents such as selexipag and riociguat, has improved survival and quality of life. Advances in gastrointestinal, renal and musculoskeletal management continue to evolve, with promising roles for intravenous immunoglobulin and..."

IO biomarker • Journal • Review • Bone Marrow Transplantation • Cardiovascular • Fibrosis • Gastrointestinal Disorder • Hypertension • Immunology • Interstitial Lung Disease • Musculoskeletal Diseases • Peptic Ulcer • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Rheumatology • Scleroderma • Systemic Sclerosis • Transplantation

OPTIMIZING RIOCIGUAT THERAPY FOR PULMONARY HYPERTENSION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF DOSE VARIABILITY, SAFETY, AND EFFICACY (CHEST 2025) - No abstract available

Retrospective data • Review • Cardiovascular • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Analysis of research trends and development prospects of soluble guanylate cyclase stimulators/activators: using bibliometric methods. (PubMed, Front Pharmacol) - "The future research hotspots will focus on the following aspects based on the current research hotspots: the safety verification of riociguat, the clinical efficacy of vericiguat for other types of heart failure, the role of praliciguat in diabetes nephropathy, and the efficacy and safety of newly discovered drugs. Furthermore, actively exploring new therapeutic directions for sGC stimulators or activators may also be an important trend in the future development of this field."

Journal • Review • Cardiovascular • Congestive Heart Failure • Diabetes • Diabetic Nephropathy • Heart Failure • Metabolic Disorders • Renal Disease

Novel mouse model to dissect cGMP-dependent platelet inhibition (ISTH 2025) - "Results were compared with NO-donor DEA-NO and pharmacological GC-stimulator riociguat...Not only did cGMP levels return to baseline within 30 seconds post-illumination and could be re-elevated, but VASP phosphorylation also decreased within 5 minutes (Fig.2). Table or Figure Upload"

Preclinical • Thrombosis

Study on the effects of different treatment methods for acute pulmonary embolism on the incidence of chronic thromboembolic pulmonary hypertension (CTEPH) and the efficacy and safety of different drug treatment regimens for CTEPH. (ChiCTR) - P=N/A | N=87 | Recruiting | Sponsor: Beijing Chao-Yang Hospital, Capital Medical University; Beijing Chao-Yang Hospital, Capital Medical University

New trial • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases

Multidisciplinary Management and Staged Surgical Treatment for Chronic Thromboembolic Pulmonary Hypertension and Subclavian Vein Thrombosis Caused by Venous Thoracic Outlet Syndrome. (PubMed, Cureus) - "Each patient was treated with anticoagulation and riociguat but had ongoing pulmonary symptoms, and staged surgical treatment was recommended...Each patient recovered well with resolution of respiratory and upper extremity symptoms and a return to unrestricted activity by three months after the second operation. These patients are some of the first to have successful staged surgical treatment for CTEPH and SCV thrombosis caused by VTOS, illustrating the value of comprehensive multidisciplinary management for this unusual combination of rare conditions."

Journal • Cardiovascular • Hematological Disorders • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases • Thrombosis • Vascular Neurology

Soluble Guanylate Cyclase Stimulator Mediated Tgf-β Induced Autophagy Related to Chronic Thromboembolic Pulmonary Hypertension (ATS 2025) - "These findings suggest that targeting autophagy may offer novel therapeutic strategies for CTEPH.These findings suggest autophagy is central to CTEPH pathogenesis and may serve as a therapeutic target. Modulating autophagy through agents like riociguat or targeting the TGF-β/Smad3 pathway may offer novel treatment strategies for CTEPH."

Cardiovascular • Fibrosis • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases • BECN1 • SMAD3 • TGFB1

Initial Experience and Short-term Outcomes of Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Patients in a New CTEPH Program in the United Arab Emirates (ATS 2025) - "Prior to PEA, all patients were treated with dual PH therapy - Riociguat and Macitentan...All patients were successfully weaned off PH medications and continued on anticoagulation with Warfarin. Our result shows an excellent outcome with no perioperative mortality and excellent improvement in hemodynamics and echocardiographic findings. PEA is a potentially curable treatment option for carefully selected CTEPH patients by skilled multidisciplinary team."

Clinical • Cardiovascular • Fibrosis • Genetic Disorders • Hematological Disorders • Pulmonary Arterial Hypertension • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases

Patients With History of Methamphetamine Use Are More Likely to Have Risk Evaluation and Mitigation Strategy Medications for Pulmonary Arterial Hypertension Stopped Due to Non-adherence (ATS 2025) - "Patients with PAH were included if they were prescribed at least one of the REMS drugs (riociguat, macitentan, ambrisentan) and had an office visit with a pulmonary hypertension specialist during the study period. Methamphetamine-associated PAH remains challenging to manage. Patients with Meth-PAH are more likely to be non-adherent to REMS drugs and active use further increases the likelihood of non-adherence. Males with Meth-PAH appear more likely to be non-adherent to REMS drugs than females."

Adherence • Clinical • Cardiovascular • Pulmonary Arterial Hypertension • Respiratory Diseases

Pulmonary Arteriovenous Malformations in BMPR2-Associated Pulmonary Arterial Hypertension (ATS 2025) - "At the time of her relocation, she was on triple oral therapy with riociguat, selexipag, and macitentan with low-risk by REVEAL score and mildly decreased right ventricular function on echocardiography. Whether sotatercept in these patients can worsen pre-existing AVMs is unknown. Figure 1."

Cardiovascular • CNS Disorders • Heart Failure • Hematological Disorders • Myasthenia Gravis • Pulmonary Arterial Hypertension • Respiratory Diseases • ACVR2A

Amphetamine Induced Group I Pulmonary Hypertension: A Case Report of Unforseen Consequences (ATS 2025) - "This abstract is funded by: None Introduction: Pulmonary hypertension (PH) is a medical condition in which there is hypertension in the lungs. In patients classified as intermediate-high risk based on their REVEAL score, PAH therapy should be initiated with endothelin receptor antagonist (bosentan), phosphodiesterase type 5 inhibitor (sildenafil), soluble guanylate cyclase stimulator (riociguat), prostanoid (epoprostenol), and/or prostacyclin agents (selexipag, and treprostinil). Treatment of PAH can be challenging as hemodynamics can be compromised with induction of these vasodilative agents; however, is necessary to prevent disease progression."

Case report • Clinical • Asthma • Cardiovascular • CNS Disorders • Congestive Heart Failure • Endocrine Disorders • Gastrointestinal Disorder • General Anxiety Disorder • Heart Failure • Hypertension • Immunology • Mood Disorders • Nephrology • Nicotine Addiction • Psychiatry • Pulmonary Arterial Hypertension • Pulmonary Disease • Renal Disease • Respiratory Diseases • Septic Shock • Tobacco Addiction

Complex Case of Melena and Epistaxis in a Patient With Advanced Pulmonary Sarcoidosis and Pulmonary Hypertension: A Multidisciplinary Approach to Management (ATS 2025) - "Two weeks prior to admission he was initiated on apixaban for pulmonary emboli...CTEPH warrants evaluation for surgical endarterectomy or pulmonary arterial balloon angioplasty, or if patient is not a candidate for either, utilization of riociguat to stimulate soluble guanylate cyclase and subsequent vasorelaxation...This case highlights the multifactorial nature of pulmonary hypertension in some patients. As such, a tailored approach to therapy is essential to address the underlying causes, and in refractory cases lung transplant may be necessary."

Clinical • Metastases • Cardiovascular • Congestive Heart Failure • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Hepatology • Immunology • Peptic Ulcer • Pulmonary Arterial Hypertension • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases • Sarcoidosis • Vasculitis

Persistence of Pulmonary Hypertension Symptoms After Two PTEs in a Patient With CTEPH (ATS 2025) - "In April 2016, she had another pulmonary embolism on rivaroxaban and was diagnosed with positive lupus anticoagulant...She started macitentan and riociguat and continued enoxaparin, but symptoms continued to worsen...Our case demonstrates that patients can still have CTEPH symptoms after a repeat PTE while on anticoagulation and PH medications. These patients might require interventions like balloon pulmonary angioplasty while continuing medical therapy and anticoagulation."

Clinical • Cardiovascular • Immunology • Infectious Disease • Inflammatory Arthritis • Novel Coronavirus Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases

Invasive Hemodynamics in the Management of Sarcoidosis Associated Pulmonary Arterial Hypertension (ATS 2025) - "Notably this was her sixth admission since February 2023 when she was started on macitentan and riociguat. The patient's PAH medications were discontinued. Sarcoidosis, especially with mixed cardio-pulmonary disease, is difficult to manage without hemodynamic assessment."

Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Disorders • Immunology • Obstructive Sleep Apnea • Pulmonary Arterial Hypertension • Pulmonary Embolism • Respiratory Diseases • Sarcoidosis • Sleep Disorder • Ventricular Tachycardia

The Phourth Pathway in PAH: Experience in the "Underserved" Central Valley of California (ATS 2025) - "Sotatercept (SOT) is the new activin inhibitor recently added as the fourth pathway...Case 1: A 45-year-old African-American female with WHO group 1 CTD-PAH reported worsening symptoms despite triple therapy (Parenteral prostacyclin therapy (PPT) + Endothelin receptor agonist (ERA) + Tadalafil (TAD)...Case 3: A 53-year-old Hispanic male with IPAH was on Triple combo treatment (Oral prostacyclin + ERA + Riociguat (Rio))... These cases illustrate favorable responses to SOT in patients with progressive PAH. Often, Symptom improvement was perceived as soon as after 1st dose. Of 4 patients, SOT had to be stopped in 1 patient due to significant Thrombocytopenia despite favorable clinical response."

Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Disorders • Immunology • Inflammatory Arthritis • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Sjogren's Syndrome • Thrombocytopenia

ATMOS, A Proof-of-Concept Trial of Inhaled Mosliciguat, A First-in-Class Soluble Guanylate Cyclase Activator - A Novel Approach to Address Unmet Needs in PH (ATS 2025) - "Phosphodiesterase 5 inhibitors and riociguat, an sGC stimulator, are approved for PH, but highly synergistic with functional, NO-responsive, heme-containing sGC. Mosliciguat had favorable tolerability and resulted in a sustained, substantial reduction in PVR after a single inhaled dose."

Cardiovascular • Fatigue • Inflammation • Pain • Pulmonary Arterial Hypertension • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases

Comparative Efficacy of Pharmacological Treatments for Inoperable Chronic Thromboembolic Pulmonary Hypertension: A Network Meta-analysis (ATS 2025) - " A comprehensive search was conducted on PubMed, Cochrane, PloSOne, ScienceDirect, Google Scholar, clinicaltrials.gov up to october 2024.Seven randomized control trials comparing seven treatments: Bosentan(A), Sildenafil(B), Macitentan(C), Riociguat(D), Ambrisentan(E) and Selexipag(F) to placebo were included. This network meta-analysis compares pharmacological treatments for inoperable CTEPH. The findings indicate that Bosentan is the most effective treatment for reducing pulmonary vascular resistance (PVR) and NT-proBNP levels, while Riociguat shows the most significant improvement in 6MWD. These results provide insights into the efficacy of available therapies, guiding clinical decision-making for patients with inoperable CTEPH."

Retrospective data • Cardiovascular • Pulmonary Arterial Hypertension • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases

Balloon Pulmonary Angioplasty and riociguat in the management of chronic thromboembolic pulmonary hypertension: a systematic review. (PubMed, Respir Med) - "Combination therapy appears to be more effective than monotherapy, without being associated to major adverse events in patients diagnosed with CTEPH."

Clinical • Journal • Review • Cardiovascular • Hypertension • Pain • Pulmonary Arterial Hypertension • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases

Bayer's Adempas gets insurance coverage in Korea 11 years after approval (Korea Biomedical Review) - "The pulmonary arterial hypertension drug Adempas (riociguat) will be covered by national health insurance starting next month -- 11 years after its approval in Korea in 2014, Bayer Korea said...According to a notice from the Ministry of Health and Welfare, Adempas will be covered for patients diagnosed with pulmonary arterial hypertension (WHO Group 1) in World Health Organization (WHO) functional classification stages 2 to 3, who have had an insufficient response to ERA (endothelin receptor blocker) and/or PDE-5 inhibitor pulmonary arterial hypertension drugs, or who are contraindicated for both ERA and PDE-5 inhibitor pulmonary arterial hypertension drugs...Adempas' reimbursement was reportedly based on clinical improvements seen in the REPLACE and PATENT studies."

Reimbursement • Pulmonary Arterial Hypertension